Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Study to determine the safety, tolerability, pharmacokinetics and immunogenicity of single
intravenous administrations of GGF2 in patients with heart failure.